You are here

A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Little Rock, Alaska, 72223 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Panic Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
13-17 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects must meet one of the following 6 diagnoses: a. A current diagnosis of panic
disorder with or without agoraphobia; b. Generalized anxiety disorder with a history
of at least one panic attack in the course of their illness; c. Social anxiety
disorder (social phobia) with a history of at least one panic attack in the course of
their illness; d. Separation anxiety with a history of at least one panic attack in
the course of their illness; e. Posttraumatic stress disorder with a history of at
least one panic attack in the course of their illness; f. Anxiety not otherwise
specified with a history of at least one panic attack in the course of their illness.

- Educational level, intelligence, or other mental condition in the subject and/or
his/her parent(s) are judged by the investigator to be sufficient to permit adequate
informed consent/assent to be obtained, and for study procedures to be complied with.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Current (in the past 6 months) diagnosis of obsessive compulsive disorder, major
depressive disorder, dysthymic disorder, or alcohol and/or substance dependence.

- Current (in the past 3 months) diagnosis of alcohol and/or substance abuse.

- Primary diagnosis of conduct disorder, oppositional defiant disorder, or Attention
Deficit Hyperactivity Disorder.

- Any current or past history of schizophrenia or psychosis; bipolar disorder or
cyclothymia; dementia, delirium or other organic brain disease; an eating disorder;
mental retardation, Asperger's disorder, or any other serious developmental disorder.

- A Childhood Depression Rating Scale, Revised score >35.

NCT00634790
Pfizer
Terminated
A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now